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Proguanil is generally well tolerated and in combination with atovaquone it is commonly used for prophylaxis of malaria. 2 Proguanil is a prodrug that is metabolized to its main active metabolite, cycloguanil, mostly via CYP2C19. [3] [4] [5] [6] [7] [8] Cycloguanil acts by inhibition of dihydrofolate reductase of the malaria parasites. 2, 9, 10 Cycloguanil is one of the few antimalarial drugs that act on both the erythrocytic and on the pre-erythrocytic (hepatic) forms of the malaria parasites. 11 The parent drug proguanil was suggested to contribute to the antimalarial activity as well, but the mechanism of action is unknown. 10 There is significant variation in proguanil pharmacokinetics. 12 CYP2C19 is the predominant enzyme catalyzing the bioactivation of proguanil to cycloguanil. Due to the heritable variants
WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?
 Proguanil is an antimalarial drug acting both on hepatic and blood schizonts. Bioactivation of proguanil to cycloguanil is highly variable and only partially explained by CYP2C19 polymorphisms. Mechanisms of cellular uptake of the hydrophilic proguanil and cycloguanil are unknown.
WHAT QUESTION DID THIS STUDY ADDRESS?
 What is the role of OCT1 in hepatocellular uptake of proguanil and cycloguanil? Does heritable OCT1 deficiency affect pharmacokinetics of proguanil and, in particular, its bioactivation to cycloguanil?
WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE?
 Hepatocellular uptake of proguanil and formation of cycloguanil seemed to be strongly dependent on OCT1 activity. Heritable OCT1 deficiency resulted in a significantly reduced cycloguanil-to-proguanil ratio. According to in vitro data with primary human hepatocytes, heritable or acquired OCT1 deficiency may cause up to fivefold reduction of cycloguanil liver (site-of-action) concentrations. HOW MIGHT THIS CHANGE CLINICAL PHARMACOLOGY OR TRANSLATIONAL SCIENCE?  OCT1 deficiency may be one cause of failure in treatment with proguanil. Proguanil exemplarily illustrates how influx transporters may be rate-limiting in drug biotransformation. CYP2C19*2 and *3 about 3% of white and African American people and about 15% of Asian people are poor CYP2C19 metabolizers 4 and have much lower cycloguanil blood concentrations. [12] [13] [14] [15] [16] The CYP2C19 variant *17 is associated with increased CYP2C19 activity, 17 but may not significantly affect proguanil or cycloguanil pharmacokinetics. 18 A smaller fraction of cycloguanil is also formed by CYP3A enzymes 4 and/or 5. [19] [20] [21] However, genetic polymorphisms in CYP2C19 and CYP3A did not, or only partially, explain treatment failures or adverse events of proguanil. 22, 23 Both proguanil and cycloguanil are hydrophilic (logD 7.4 = −0.6 and −1.8, respectively) and >99% positively charged under physiological conditions (pK a = 11.8 and 10.5, respectively). Therefore, proguanil and cycloguanil can only poorly pass through membranes by passive diffusion and it is very likely that organic cation transporters are involved in the hepatic uptake of proguanil. This carrier-mediated uptake could be an essential first step both for bioactivation to cycloguanil and for reaching the hepatic site of action of cycloguanil after its first release into the bloodstream.
The most strongly expressed organic cation transporter in the sinusoidal membrane in the human liver is organic cation transporter (OCT)1. [24] [25] [26] OCT1 is highly genetically polymorphic. Five common amino acid substitutions (Arg61Cys, Gly401Ser, Ser14Phe, Cys88Arg, and Gly465Arg) and a deletion of methionine 420 (Met420del) are known to cause either complete loss or a substrate-specific strong reduction of OCT1 activity. Depending on the substrate, between 3 and 9% of white people carry two deficient OCT1 alleles. [27] [28] [29] Individuals with two inactive OCT1 alleles are known to have altered pharmacokinetics, efficacy, and toxicity of drugs, like metformin, morphine, tramadol, fenoterol, and tropisetron. 26, [30] [31] [32] [33] [34] [35] [36] [37] Similar to proguanil, some of the known OCT1 substrates, like metformin 32 and debrisoquine, 38 contain a guanidine or biguanide moiety in their chemical structures.
Here, we studied whether proguanil and its active metabolite cycloguanil are substrates of OCT1 and whether the hepatic production of cycloguanil may be limited by OCT1 and, thus, the intracellular concentrations of cycloguanil may be reduced in case of OCT1 deficiency. In addition, we analyzed whether OCT1 genetic polymorphisms affect proguanil and cycloguanil pharmacokinetics in humans. These data may help to improve tolerability and efficacy in malaria prophylaxis with proguanil, and also extends our knowledge about the role of organic cation transporters in pharmacokinetics of weakly basic drugs acting in the liver.
RESULTS

Cellular uptake of proguanil and cycloguanil via OCT1
The cellular uptake of proguanil and cycloguanil was strongly increased by OCT1 (Figure 1a,b) . At clinically relevant concentrations, the uptake into HEK293 cells overexpressing OCT1 was eightfold higher for proguanil and 11.5-fold higher for cycloguanil, compared with control cells (Figure 1c,d) . The OCT1-mediated uptake followed Michaelis-Menten kinetics with K M values of 17.7 and 18.3 μM and V max values of 2,314 and 1,300 pmol/mg protein/min for proguanil and cycloguanil, respectively. OCT3, the other organic cation transporter expressed in the sinusoidal membrane of hepatocytes, transported proguanil and cycloguanil less efficiently than OCT1 did (Figure 1a,b) . The intrinsic clearance of proguanil via OCT1 was >10-fold higher than the intrinsic clearance via the alternative hepatic transporter OCT3 ( Table S1 ). The affinity and maximum velocity of cycloguanil uptake was similar between OCT1 and OCT3. However, considering the >10-fold higher hepatic expression of OCT1 compared to OCT3, 24, 25 we concluded that OCT1 is the relevant hepatic transporter of both proguanil and cycloguanil.
We then analyzed the cellular uptake of proguanil and cycloguanil by common allelic variants of OCT1. Proguanil uptake was moderately reduced by the worldwide common OCT1 variant *2 (71% of the wild-type allele), and was strongly reduced by the OCT1 variants *3 and *4 (44% and 20% of the wild type, respectively; Figure 1c ), which are frequent OCT1 variants among European populations. In contrast, cycloguanil uptake was only moderately reduced by the variants *3 and *4 (79% and 61% of the wild type, respectively) and not affected by the OCT1*2 variant at all (Figure 1d ). Neither proguanil nor cycloguanil was taken up by cells overexpressing OCT1*5 and *6 (Figure 1c,d) . The OCT1*7 variant is relatively frequent in some populations living in areas with a high incidence of malaria 28, 29 ; the uptake activity of OCT1*7 was reduced by only 25% for proguanil and unchanged for cycloguanil (Figure 1c,d ). In conclusion, several naturally occurring variants of OCT1 significantly reduce the cellular uptake of proguanil and cycloguanil.
Effects of OCT1 polymorphisms on proguanil and cycloguanil pharmacokinetics in humans Based on the in vitro data supporting a role for OCT1 in proguanil and cycloguanil transport, we performed a clinical study in healthy volunteers to assess the effects of OCT1 genotype on the pharmacokinetics of proguanil and cycloguanil. Proguanil was administered to 39 subjects preselected to achieve an enrichment of carriers of OCT1 alleles *2, *3, and *4. We also wanted to include carriers of OCT1 alleles *5 and *6, but no carriers of these alleles could be found for this study. We included 22 carriers of two active OCT1 alleles, 13 carriers of one fully active allele and one deficient allele, and 4 carriers of two deficient alleles. According to the in vitro data, the alleles OCT1*1 and *2 were classified as active in proguanil transport and the alleles *3 and *4 as deficient but noting that both alleles had some proguanil transport activity ( Figure 1) .
The concentration-time profiles of proguanil showed substantial interindividual variation both in whole blood and in plasma. The AUCs of proguanil in blood varied almost threefold (range = 361-1061 μg*min/mL; Figure S1 ). The interindividual variation in cycloguanil concentrations was even greater. Cycloguanil AUCs measured in blood varied >10-fold (range = 12-130 μg*min/mL). Correspondingly the ratio of cycloguanil-to-proguanil AUCs varied >20-fold (range = 0.012-0.249).
Predefined primary parameters were proguanil and cycloguanil AUCs. Proguanil AUC was on average about 10% higher in carriers of zero compared with carriers of two active OCT1 alleles ( Figure 2 and Table 1) but the difference was not statistically significant. Correspondingly, the maximum concentrations were insignificantly higher and the volume of distribution (V z /F) was smaller in carriers of zero active alleles ( Table 1) . In contrast, the mean AUC of cycloguanil in blood was 50% higher in subjects carrying one or two active alleles compared to carriers of zero fully active OCT1 alleles (P = 0.03; Table 1 and Figure 2c ,d).
The relevance of OCT1 genotypes for the metabolic conversion of proguanil to cycloguanil in humans becomes more evident when depicting the ratio of cycloguanil to proguanil, which was highly dependent on OCT1 genotype (Figure 2e ). In carriers of zero active OCT1 alleles, the AUC ratios for cycloguanil-to-proguanil were 68% lower than in carriers of two active OCT1 alleles ( Figure 2f and Table 1) .
Dependence of cycloguanil AUC and of the cycloguanil/ proguanil ratio was additionally supported by the correlation of these parameters with the in vitro exact OCT1 activity score. The exact in vitro activity scores were calculated using the relative in vitro proguanil uptake data for each OCT1 allele ( Figure 1c ) as described elsewhere. 35 The in vitro OCT1 activity scores varied from 0.64 to 2 among the volunteers and the ratios of the cycloguanil to proguanil AUCs decreased close to linearly for scores below 1.44 and remained constant for the higher in vitro OCT1 activity scores ( Figure 2g ). This indicates that a combination of one active and one partially active allele is sufficient for the unrestricted Concentration-time curves for proguanil (a), and cycloguanil (c), and the cycloguanil-to-proguanil ratio over time (e) in whole blood. The healthy volunteers were stratified according to their OCT1 genotype in terms of number of fully active OCT1 alleles. According to the in vitro data alleles OCT1*1 and OCT1*2 were regarded fully active and alleles OCT1*3 and OCT1*4 not. Shown are means and SDs of the means. Also shown are the areas under the time concentration curves (AUCs) of proguanil (b), cycloguanil (d) and the ratio of cycloguanil AUC divided to proguanil AUC (f) in whole blood. Shown are medians and the quadrantile for each OCT1 genotype. The significance was calculated using the Jonckheere-Terpstra trend test. (g) Cycloguanil-to-proguanil AUC ratios are dependent on the in vitro OCT1 activity scores. The in vitro activity scores were calculated according to the in vitro data for proguanil uptake assuming an additive mode of inheritance (see Figure 1) . The activity scores are also represented as color change from green (high activity) to red (no OCT1 activity).
biotransformation of proguanil to cycloguanil. The most common variant allele OCT1*2 exhibited only a minor effect in vitro and in vivo; homozygous OCT1*2 allele carriers had an insignificant 22% reduction of the cycloguanil-to-proguanil ratios ( Figure S2) .
The pharmacokinetics of proguanil and cycloguanil were also analyzed in plasma. The effects of the OCT1 genotypes were similar to those found in whole blood ( Figure S3 and Table S3 ). As described previously, 1 proguanil was rapidly and strongly accumulated in erythrocytes ( Figure S4 ), resulting in up to 4.3-fold higher concentrations of the drug in whole blood than in plasma (median AUCratio of 3.3, range = 2.2-4.3). There were no significant differences in the proguanil accumulation in erythrocytes between the different OCT1 genotypes ( Figure S4 ). In big contrast to proguanil, uptake of cycloguanil into erythrocytes was apparently slow ( Figure S4) .
Finally, we analyzed the OCT1 effects on proguanil and cycloguanil pharmacokinetics in the context of other genetic and nongenetic factors. Body weight, sex, smoking, CYP2C19 and CYP3A polymorphisms, and OCT1 polymorphisms were included in the multiple linear regression analyses (Table S4) .
From the nongenetic factors, body weight had significant effects on the AUC of proguanil. In addition, cycloguanil formation, when expressed as the cycloguanil/proguanil ratio, was significantly dependent on sex (Table S4) . Among the women, there were no significant differences in the proguanil or cycloguanil AUC or the cycloguanil-to-proguanil ratio between users and nonusers of hormonal contraceptives.
Among the genetic factors, the known effect of the CYP2C19*2 genotype was confirmed in this study ( Figure 3 and Table S4 ). The CYP3A5*3 allele but not the CYP3A4*22 allele was associated with cycloguanil AUCs and with cycloguanil-to-proguanil ratios. Individuals with active CYP3A5 (heterozygous carrier of CYP3A5*1 allele, n = 5) had 35% lower cycloguanil AUCs and 42% lower cycloguanil-toproguanil ratios. However, this study was not designed to draw firm conclusions about CYP2C19 and CYP3A polymorphisms.
Importantly, the effects of OCT1 deficiency on cycloguanil concentration and on the cycloguanil-to-proguanil ratios remained significant after considering the effects of the other genetic and nongenetic factors known (Table S4) . Effects of OCT1 on the hepatic uptake of proguanil and on the production and hepatocellular accumulation of cycloguanil
We used primary human hepatocytes to study in vitro the role of OCT1 in the hepatocellular uptake of proguanil and its bioactivation to cycloguanil in the liver and to estimate the intrahepatic concentrations of cycloguanil by OCT1-deficiency. Proguanil uptake into the hepatocytes was significantly reduced in the presence of the OCT1 inhibitor MPP + (Figure 4 ). Under this OCT1 inhibition, the concentrations of proguanil in hepatocytes were as much as 2.5-fold lower (Figure 4b ) and formation of cycloguanil was substantially reduced. Under OCT1 inhibition, cycloguanil released into the cell culture medium after 90 minutes was reduced 4.2-fold (Figure 4c) . The intracellular concentrations of cycloguanil were decreased as much as 5.2-fold (Figure 4d ).
This experiment clearly shows the rate-limiting role of OCT1 in the hepatic biotransformation of proguanil to its active metabolite cycloguanil and suggests that OCT1 deficiency may lead to strongly reduced concentrations of therapeutically active cycloguanil in the liver.
DISCUSSION
This study suggests that the hepatic uptake of proguanil depends on the organic cation transporter OCT1. It also shows that reduced or absent OCT1 activity due to genetic polymorphisms or OCT1 inhibition leads to reduced cycloguanil production and substantially lower intrahepatic concentration of cycloguanil. This was clearly demonstrated both by the in vitro data (Figures 1  and 4) and by the cycloguanil-to-proguanil ratios in blood after an oral administration of proguanil to healthy volunteers ( Figure 2) . The hepatic (target organ) concentrations of cycloguanil could not be measured in humans, but the experiments with primary human hepatocytes ( Figure 4) suggest substantially reduced intrahepatic concentrations of cycloguanil in individuals with genetic OCT1 deficiency.
Our data strongly suggests that genetic OCT1 deficiency may compromise proguanil efficacy, particularly in hepatocytes and to a lesser extent in erythrocytes. The human pharmacokinetic data shows rate-limiting effects of OCT1 in the hepatic bioactivation of proguanil to cycloguanil. Furthermore, inhibition of OCT1, which may be comparable with complete loss of OCT1 activity in homozygous or compound heterozygous carriers of OCT1*5 and *6 alleles, led to fivefold lower cycloguanil concentrations in hepatocytes ( Figure 4) . This may be similar to the effects known for the structurally related drug metformin where the OCT1 dependent hepatic accumulation was elegantly confirmed recently also in vivo. 34 On the other hand, the OCT1-mediated differences in the hepatic uptake and metabolism of proguanil resulted in only a limited increase of the proguanil concentrations in systemic circulation ( Figure 2) . Without further pharmacodynamic data, it remains unclear to what extent an observed about 50% reduction of cycloguanil concentrations in the systemic circulation due to reduced hepatic bioactivation of proguanil, and presumably a subsequent reduction within erythrocytes may affect the antiparasitic activity within the erythrocytes.
In the volunteers studied here, OCT1 deficiency led to reduced cycloguanil blood concentrations, but not to significantly increased proguanil concentrations. In vitro experiments clearly showed that both proguanil and cycloguanil are substrates of OCT1 and that the variants OCT1*3 and OCT1*4 strongly reduced proguanil uptake (Figure 1a,c) and inhibition of OCT1 in primary hepatocytes resulted in impaired proguanil uptake ( Figure 4) . One might expect that reduced hepatic uptake results in increased plasma concentrations, as shown for other drugs in the case of OCT1 or OATP1B1 deficiency. 39, 40 Similar to metformin, 34, 41 there was, however, only a minor increase of the blood concentrations of proguanil in subjects with OCT1 deficiency (0, 1, or 2 inactive OCT1 alleles). Corresponding with the in vitro data (Figure 4) , volume of distribution of proguanil was nominally smaller in carriers of low-activity OCT1 alleles. The moderate (only about 10%) decrease in volume of distribution and increase in proguanil AUC in volunteers with two low-activity OCT1 alleles may not be surprising for a number or reasons. First, proguanil has a large volume of distribution in general so that the delayed access to the liver does not change the volume of distribution very much. Second, we did not find carriers of two completely deficient alleles but only carriers of low-activity alleles. Third, there is some extrahepatic biotransformation of proguanil, particularly in the small intestines, but OCT1 is not (or not to a relevant extent) expressed at the apical side of the enterocytes. Fourth, about 50% of proguanil is recovered unchanged in the urine after oral administration 42 and recent experimental data indicates that renal elimination of both proguanil and cycloguanil may be mediated by OCT2 and MATE2-K transporters.
43 Figure 3 Combined effects of organic cation transporter (OCT)1 genotypes and CYP2C19 genotypes (symbols) on the cycloguanilto-proguanil ratios. Shown are the ratios of cycloguanil areas under the time concentration curves (AUC) to proguanil AUC for each healthy volunteer tested. The figure confirms the strong effects of CYP2C19 deficiency (*2/*2 genotype) on cycloguanil production, but also demonstrates the CYP2C19-independent effects of OCT1.
The effects of OCT1 polymorphisms on proguanil and cycloguanil pharmacokinetics may be stronger than observed in this study in those individuals with more rare alleles conferring complete loss of OCT1 activity such as the alleles OCT1*5 or OCT1*6. Both, proguanil and cycloguanil are substrates of OCT1, but the effects of the common OCT1 polymorphisms vary between the two substrates ( Figure 1) . According to the effects of OCT1 polymorphisms, we could define three groups ( Figure 5 ): individuals with both highly active proguanil and cycloguanil uptake (carriers of the OCT1*1 and *2 alleles; Figure 5b ), individuals with highly active cycloguanil, but impaired proguanil uptake (carriers of the OCT1*3 and *4 alleles; Figure 5c ), and individuals with both impaired proguanil and cycloguanil uptake in the liver (carriers of the OCT1*5 and *6 alleles; Figure 5d ). In our clinical studies, we compared only individuals from the first and the second groups. Impairment of proguanil uptake in individuals from the second group was sufficient to cause substantial changes in the pharmacokinetics of cycloguanil and especially in the cycloguanil-to-proguanil ratio. The changes in the cycloguanil pharmacokinetics and especially in the intrahepatic concentrations of cycloguanil may be expected to be much more pronounced in the individuals of the third group carrying the complete loss of any OCT1 activity. In this case, the effects may be comparable with the effects of OCT1 inhibition performed in the experiments with primary hepatocytes (Figure 4) . On average, 1 out of 2,300 Europeans or white Americans is expected to belong to the third group: homozygous or compound heterozygous carriers of alleles OCT1*5 and/or *6. 28 However, in some populations, this number may be as high as 1 of 200 individuals. 28 The high variability in the pharmacokinetics of proguanil and particularly of cycloguanil is well known. 7, 12, 13, [44] [45] [46] Polymorphisms in CYP2C19 cause strong variation in cycloguanil production, 22 and the CYP3A enzymes 19 and hormonal contraception 47 have Figure 4 Effects of organic cation transporter (OCT)1 inhibition on uptake of proguanil and production of cycloguanil in primary human hepatocytes. Primary human hepatocytes were incubated with 1 µM proguanil in the presence and in the absence of 1 mM of the OCT1-inhibitor MPP + . Shown are means and standard error of means of hepatocytes obtained from two donors measured in two independent experiments each. Shown are means and SEs of the means of the extracellular (a) and (c) and intracellular (b) and (d) concentrations of proguanil (a) and (b) and cycloguanil (c) and (d) from four independent experiments. Note that cycloguanil was not added to the cell culture medium, but generated within the human hepatocytes. Both cell lines were wild-type concerning CYP2C19 genotypes (no *2 and *17 alleles found) and both cell lines also did not carry the CYP3A4*22 allele, but one carried the active CYP3A5*1/*3 genotype whereas the other carried the deficient CYP3A5*3/*3 genotype.
been reported to play a role. Here, we report heritable OCT1 deficiency as a significant, independent predictor of proguanil bioactivation that further explained the pharmacokinetic variability ( Figure 3 and Table S4 ).
Regarding potential drug-drug interactions, a recently published in vitro study suggested that a number of antimalarial drugs may inhibit OCT1 uptake. 43 No clinically relevant drug-drug interaction may be expected with the co-administered atovaquone, but the proguanil-quinine combination, for example, may not be advisable according to these data.
There were some limitations in our clinical study. First, we did not collect urine samples. Therefore, we could not specifically analyze the effects of OCT polymorphisms on renal clearance. Second, we had a relatively small number of homozygous carriers of the OCT1*3 and OCT1*4 alleles and there were no homozygous or compound heterozygous carriers of the completely uptake-deficient OCT1*5 and OCT1*6 alleles. Our study was planned based on the assumption that, as with substrates, like metformin, tramadol, or morphine, the OCT1*2 allele would confer significant reduction in the uptake. It turned out that this was not the case and the OCT1*2 carriers should be regarded as active when considering proguanil and cycloguanil membrane transport. Even with the relatively small number of carriers of zero active OCT1 alleles, we observed significant effects on cycloguanil production. Finally, we did not measure efficacy. Although that would medically be the most relevant study, the frequency of carriers of zero active OCT1 alleles is very low in regions with high malaria incidence, like Africa and Asia, 28 making such studies difficult. Animal experiments may be a next and more feasible step.
In conclusion, OCT1-mediated uptake can be a limiting step in hepatic bioactivation of proguanil to cycloguanil. In addition to genetic variability in the metabolizing enzyme CYP2C19, heritable OCT1 deficiency may contribute to the high variability in cycloguanil formation after proguanil administration. Proguanil may be an interesting example in that the effect of genetic polymorphisms in drug transport on drug concentrations may be much greater at the target site than indicated by the blood concentrations.
METHODS Uptake measurements in HEK293 cells and hepatocytes
OCT1-overexpressing HEK293 cell lines were stably transfected by targeted genome integration using the Flp-In system (Thermo-Fisher Scientific, Darmstadt, Germany). Generation Figure 5 Schematic representation of the role of organic cation transporter (OCT)1 (a) and OCT1 polymorphisms (b-d) in the hepatic metabolism of proguanil. OCT1 plays a role both in the uptake of proguanil and of its metabolite cycloguanil into the human liver (a). In contrast to individuals with two active OCT1 alleles (OCT1*1 or *2) (b), individuals with OCT1*3 or *4 alleles are expected to have reduced proguanil uptake and, thus, reduced cycloguanil production (c). Individuals with OCT1*5 or *6 alleles will be impaired both in the uptake of proguanil and cycloguanil and will have the strongest reduction of intrahepatic cycloguanil concentrations (d). Recent data indicates that OCT1 may also act as an efflux transporter 48 and may, thus, mediate efflux of cycloguanil from the hepatocytes, but according to our experimental data also other transporters and passive diffusion may contribute to cycloguanil efflux from the hepatocytes. and characterization of the overexpressing cells has been described elsewhere. 28, 38 The cellular uptake experiments were performed as described before 35 with some modifications (see Supplementary  Methods) .
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Hepatic uptake and biotransformation were analyzed in cryopreserved human hepatocytes from two donors (Supplementary Methods). Intracellular concentrations of proguanil and cycloguanil were quantified by liquid chromatography tandem mass spectrometry (Supplementary Methods).
Genotyping of OCT1 and CYP2C19
Genotyping of the OCT1 polymorphisms Met420del (OCT1*2, rs202220802), Arg61Cys (OCT1*3, rs12208357), Gly401Ser (OCT1*4, rs34130495), Gly465Arg (rs34059508, OCT1*5 in combination with Met420del), Cys88Arg (rs55918055, OCT1*6 in combination with Met420del), Ser14Phe (rs34447885), Pro117Leu (rs200684404), and Ser189Leu (rs34104736) was performed using single-base primer extension with fluorescently labeled dideoxynucleotides (SNaPshot; Life Technologies, Darmstadt, Germany). The procedure has been described in detail elsewhere. 28 The polymorphism Arg488Met (rs35270274) in OCT1 and the CYP2C19 variants *2 and *17 (rs4244285 and rs12248560, respectively) were genotyped using a TaqMan SNP genotyping assay (Life Technologies).
Clinical study
The study was approved by the Ethics Committee of the University Medical Center Göttingen (application number 18/8/12) and by the German Federal Drug Administration (BfArM, submission code 4038436). It was registered in the European clinical trials database (EudraCT-number 2012-003546-33) and in the clinical trials database ClinicalTrials.gov (NCT02054299). All subjects gave their written informed consent before participation.
We administered 200 mg proguanil (Paludrine; AstraZeneca GmbH, Wedel, Germany) orally to 39 unrelated healthy subjects. Healthy men and women aged 18-50 years and with a body mass index between 17 and 33 kg/m 2 were included. Health status was confirmed by medical history, medical examination, electrocardiogram, urine status, and clinical chemistry analyses, including sodium, potassium, total bilirubin, aspartate transaminase, alanine transaminase, creatinine, C reactive protein, thyroid stimulating hormone, and hemoglobin, as well as erythrocyte, thrombocyte, and leucocyte counts.
After overnight fasting, all subjects received two 100 mg tablets of proguanil. Whole blood and plasma was sampled before and 0.5, 1, 2, 3, 4, 6, 8, 10, 24, and 36 hours after administration of proguanil. Blood samples for analyzing plasma concentrations were centrifuged at 22°C for 10 minutes (3,100 g) and then stored at −20°C before concentration analyses. Whole blood was immediately stored at −20°C. The plasma and whole blood concentration analyses were performed by liquid chromatography tandem mass spectrometry (Supplementary Methods). Adverse events were recorded over the whole study period.
Pharmacokinetics
Pharmacokinetic parameters were estimated with noncompartmental methods using the Phoenix WinNonlin software version 6.3 (Certara USA, Princeton, NJ). The primary parameter AUC was calculated with the linear/log trapezoidal rule from time of proguanil administration and extrapolated to infinity based on the last predicted concentrations. Clearance was calculated as dose divided by AUC. The terminal elimination rate constant lambda z was used to calculate terminal half-life and the volume of distribution V z /F (=dose/(lambda z * AUC)). The time of maximum concentration (T max ) and the corresponding concentration (C max ) were given as observed. Metabolic ratios are given as mass ratios, with molecular weights of 251.72 and 253.73 for cycloguanil and proguanil, respectively, molar metabolic ratios would be minimally smaller (conversion factor 0.992).
Statistics
Predefined primary parameters were the AUCs from zero to infinity of proguanil and cycloguanil. A sample size of 14 poor and 14 extensive transporters was estimated prior to start of the study to give 80% power to identify a 50% increase in the AUC. Thus, the study was enriched with poor transporters preselected from our healthy volunteer's database to increase statistical power. Only after termination of the study the in vitro data (which are also presented in this manuscript) showed that carriers of allele OCT1*2 had high proguanil and cycloguanil transport activity, and these 10 volunteers had, thus, to be reclassified as extensive transporters. The nonparametric JonckheereTerpstra trend test was used in testing the primary hypotheses. Figure S2 . Effects of OCT1 allele *2 on the in vivo transport and biotransformation of proguanil to cycloguanil in humans. Figure S3 . Effects of OCT1 polymorphisms on the pharmacokinetics of proguanil and cycloguanil in plasma. Figure S4 . Exploration concerning possible effects of OCT1 genotypes on proguanil and cycloguanil accumulation in erythrocytes. Table S1 . Transport-kinetic constants describing cell uptake of proguanil and cycloguanil by OCT1 and OCT3. Table S2 . Demographic data of the studied healthy volunteers stratified for OCT1 genotype given as number of active alleles. Table S3 . Pharmacokinetics of proguanil and cycloguanil in plasma. Table S4 . Multifactorial analysis of other parameters potentially affecting AUC of proguanil and cycloguanil in whole blood. Appendix S1. OCT1 deficiency affects hepatocellular concentrations and pharmacokinetics of cycloguanil, the active metabolite of the antimalarial drug proguanil.
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